Date: 2011-09-21
Type of information:
phase: 2
Announcement: initiation
Company: NovImmune (Switzerland)
Product: NI-0801
Action mechanism: This fully human monoclonal antibody is able to neutralize the CXCL10/Interferon-gamma-inducible protein-10 (IP-10) chemokine.
Disease: primary biliary cirrhosis
Therapeutic area: Rare diseases Autoimmune diseases
Country: UK, Italy
Trial
details: The PIANO study: Primary biliary cirrhosis: Investigating A New treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody,
Latest news: NovImmune has initiated a Proof-of–Concept (PoC) study with NI-0801 in patients with primary biliary cirrhosis (PBC). This chronic inflammatory, debilitating condition of the bile ducts leads to liver cirrhosis and eventually to liver failure. PBC is an orphan, autoimmune, progressive liver disorder that primarily affects females. CXCL10/IP-10 is secreted by several cell types in response to inflammation and contributes significantly to the entry of immune cells into the liver. These cells are responsible for the destruction of the biliary tract in PBC and, with time, provoke the dysregulated scarring process which characterizes the late stages of the disease. The neutralization of CXCL10/IP-10 with NI-0801 offers the possibility to interfere with one of the key inflammatory processes that leads to PBC.
